RAS Mutation Clinical Trials in Washington D.C., District of Columbia
3 recruitingWashington D.C., District of Columbia
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 1
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Solid TumorKRAS Mutation-Related Tumors
Georgetown University24 enrolled1 locationNCT05661201